行情

ACRX

ACRX

AcelRx制药
NASDAQ

实时行情|Nasdaq Last Sale

2.650
+0.040
+1.53%
盘后: 2.630 -0.02 -0.75% 18:51 09/18 EDT
开盘
2.600
昨收
2.610
最高
2.720
最低
2.550
成交量
74.70万
成交额
--
52周最高
5.05
52周最低
1.990
市值
2.11亿
市盈率(TTM)
-3.7011
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ACRX 新闻

  • 微软宣布400亿美元股票回购 盘后股价上涨1.3%
  • 新浪美股.3小时前
  • 新iPhone预售“真香” 苹果公司却一年痛失三位高管
  • 新浪美股.3小时前
  • 罢工导致工厂放缓 通用汽车在加拿大临时裁员1200人
  • 新浪美股.3小时前
  • 一文读懂美联储降息:年内第二次降息 遭特朗普"炮轰"
  • 新浪美股.3小时前

更多

所属板块

生物技术和医学研究
-0.68%
制药与医学研究
-0.14%

热门股票

名称
价格
涨跌幅

ACRX 简况

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.
展开

Webull提供AcelRx Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。